Clinical Features of Type B Insulin Resistance in Japanese Patients: Case Report and Survey-Based Case Series Study

Table 1

Changes in serum levels of FBG, insulin, C-peptide, HbA1c, glycoalbumin, anti-insulin receptor antibody, and insulin receptor inhibition rate.

Hospital day	0	1	21	43	49	58	64	72	78	85
FBG (mg/dL)	(587); Random	(370); Random	351	382	392	116	109	72	63	76
FBG (mmol/L)	(32.6); Random	(20.6); Random	19.5	21.2	21.8	6.44	6.06	4.00	3.50	4.22
FIRI (μU/mL)	(1340); Random	(929); Random		1088	536	64	43	15	12	11
FCPR (ng/mL)	(15.7); Random	(9.1); Random	5.6	11.4	8.2	4.5	4.6	2.1	2.5	2.3
HOMA-IR						18.3	11.6	2.7	1.9	2.1
HOMA-β (%)						435	337	600		305
CPI						3.87	4.22	2.92	3.97	3.03
HbA1c (%)		7.2	10.6	11.9					11.9
HbA1c (mmol/mol)		55.2	92.3	106					106
Glycoalbumin (%)		28.1		41.6	46.5	41.3	37.2	32.2	28.1	24.5
Anti-insulin receptor antibody		+		+			–
Insulin receptor inhibition rate (%)		71.3		74.7			1.4

FBG: fasting blood glucose; FIRI: fasting immunoreactive insulin; FCPR: fasting C-peptide; HOMA-IR: homeostasis model assessment for insulin resistance; HOMA-β: homeostasis model assessment for beta cell function; CPI: C-peptide index (100x fasting CPR/FBG).